You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Ovarian Cancer Virtual Patient Case Simulation: How Do You Incorporate Maintenance Therapy?

  • Authors: Bradley Monk, MD, FACOG, FACS; David O’Malley, MD
  • CME / ABIM MOC Released: 3/27/2023
  • Valid for credit through: 3/27/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, obstetricians/gynecologists, and pathologists.

The goal of this activity is for learners to be better able to provide oncologists and other members of the ovarian cancer healthcare team with a virtual, hands-on experience that allows them to gain knowledge, confidence, and competence in incorporating maintenance therapy for the management of patients with ovarian cancer. 

Upon completion of this activity, participants will:

  • Demonstrate improved performance associated with:
    • Selecting the most appropriate diagnosis for a patient with advanced ovarian cancer
    • Ordering relevant tests to determine eligibility for treatment options
    • Selecting appropriate treatment recommendations for frontline maintenance therapy in ovarian cancer
    • Counseling patients on potential treatment-related adverse events associated with frontline maintenance therapies


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Bradley Monk, MD, FACOG, FACS

    Division of Gynecologic Oncology
    College of Medicine–Phoenix
    Phoenix, Arizona


    Bradley Monk, MD, FACOG, FACS, has the following relevant financial relationships:
    Consultant or advisor for: Acrivon Therapeutics, AdaptImmune Therapeutics, Agenus, Akeso Therapeutics, Amgen, Aravive, AstraZeneca, Bayer, Clovis Oncology, Eisai, Elevar Therapeutics, Genmab/Seagen Inc., Gradalis, Hengrui Pharma, ImmunoGen, Karyopharm Therapeutics, Iovance Biotherapeutics, Laekna Therapeutics, MacroGenics, Merck & Co., Inc., Mersana Therapeutics, Myriad Genetics, Novartis, Novocure, OncoC4, Panavance Therapeutics, Pieris Pharmaceuticals, Pfizer, Puma Biotechnology, Regeneron Pharmaceuticals, Roche/Genentech, Sorrento Therapeutics, TESARO, GlaxoSmithKline, US Oncology Research, VBL Therapeutics, Verastem Oncology, Zentalis Pharmaceuticals
    Speaker or member of speakers bureau for: AstraZeneca, Clovis Oncology, Eisai, Merck & Co., Inc., Myriad Genetics, Roche/Genentech, TESARO/GlaxoSmithKline
    Contracted researcher for: Gradalis, US Oncology Research

  • David O’Malley, MD

    Professor and Director
    Division of Gynecologic Oncology
    Ohio State University and the James Cancer Center
    Columbus, Ohio


    David O’Malley, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, AdaptImmune Therapeutics, Agenus, Arquer Diagnostics, Arcus Biosciences, AstraZeneca, Atossa Therapeutics, Boston Biomedical, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Bio, Eisai, Elevar Therapeutics, Exelixis, Genentech, Genelux, GlaxoSmithKline, GOG Foundation, Hoffmann-La Roche, ImmunoGen, Imvax, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen, Jazz Pharmaceuticals, Laekna Therapeutics, Leap Therapeutics, Luzsana Biotechology, Merck & Co., Inc, Merck Sharp & Dohme Corp., Mersana Therapeutics, Myriad Genetics, Novartis, NovoCure, OncoC4, Onconova Therapeutics, Regeneron Pharmaceuticals, RepIimune, R-Pharm, Roche Diagnostics, Seagen Inc., Sorrento Therapeutics, Sutro Biopharma, Tarveda Therapeutics, Toray, Trillium Therapeutics, Umoja Biopharma, Verastem Oncology, VBL Therapeutics, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals
    Research funding from: AbbVie, Advaxis, Agenus, Alkermes, Aravive, Arcus Biosciences, AstraZeneca, Atossa Therapeutics, BeiGene, Boston Biomedical, Bristol-Myers Squibb, Clovis Oncology, Deciphera Pharma, Eisai, EMD Serono, Exelixis, Genentech, Genmab, GlaxoSmithKline,  Hoffmann-La Roche, ImmunoGen, Incyte Corporation, Iovance Biotherapeutics, Karyopharm, Leap Therapeutics, Merck & Co., Inc., Merck Sharp & Dohme Corp., Mersana Therapeutics, NCI, Novartis, NovoCure, NRG Oncology, OncoC4, OncoQuest, Pfizer, Precision Therapeutics, Prelude Therapeutics, Regeneron Pharmaceuticals, Rubius Therapeutics, Seagen, Sutro Biopharma, TESARO, Verastem Oncology


  • Stephanie Baumhover, PharmD, BCPS

    Medical Education Director, Medscape, LLC


    Stephanie Baumhover, PharmD, BCPS, has no relevant financial relationships.

  • Katie Prince

    Writer, Chichester Associates, Phoenix, Arizona


    Katie Prince has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS ( 

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Ovarian Cancer Virtual Patient Case Simulation: How Do You Incorporate Maintenance Therapy?

Authors: Bradley Monk, MD, FACOG, FACS; David O’Malley, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/27/2023

Valid for credit through: 3/27/2024, 11:59 PM EST


Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices and drugs using an intuitive patient chart-based interface.

Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

  • Print